blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2119452

EP2119452 - PHARMACEUTICAL COMPOSITION, COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.01.2021
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  31.01.2020
FormerGrant of patent is intended
Status updated on  29.10.2019
Most recent event   Tooltip24.06.2022Lapse of the patent in a contracting state
New state(s): CY, HU, MT		published on 27.07.2022  [2022/30]
Applicant(s)For all designated states
Centro de Inmunologia Molecular
Calle 216 esq. 15, Atabey Playa, Ciudad de la Habana, AP. 16040
Ciudad de la Habana 12100 / CU
[2020/10]
Former [2009/47]For all designated states
Centro de Inmunologia Molecular
Calle 216 esq. 15, Atabey Playa, Ciudad de la Habana, AP. 16040
Ciudad de la Habana 12100 / CU
Inventor(s)01 / MONTERO CASIMIRO, José Enrique
Calle 314 No. 2916 entre 29 y 31
Juan de Dios Fraga, La Lisa
Ciudad De La Habana 17100 / CU
02 / CASACO PARADA, Ángel Raimundo
Calle 82 No. 3316 Apto 15 e/33a Y 39
Marianao
Ciudad de la Habana / CU
03 / MAZORRA HERRERA, Zaima
Calle 180 e/ 1ra y 5ta Edif. BAE Apto 19
Reparto Flores, Playa
Ciudad De La Habana / CU
04 / ALONSO RAMIREZ, Ruby
Ave 41 No. 6408, entre 64 y 66
San José de las Lajas, Provincia Habana / CU
05 / PEREZ RODRIGUEZ, Rolando
Juan Delgado 567 e/. Acosta y O'farrill, 10 de Oc
t.
Ciudad De La Habana / CU
 [2020/10]
Former [2009/47]01 / MONTERO CASIMIRO, José Enrique
Calle 314 No. 2916 entre 29 y 31 Juan de Dios Fraga, La Lisa
Ciudad De La Habana 17100 / CU
02 / CASACO PARADA, Ángel Raimundo
Calle 82 No. 3316 Apto 15 e/33a Y 39 Marianao
Ciudad de la Habana / CU
03 / MAZORRA HERRERA, Zaima
Calle 180 e/ 1ra y 5ta Edif. BAE Apto 19 Reparto Flores, Playa
Ciudad De La Habana / CU
04 / ALONSO RAMIREZ, Ruby
Ave 41 No. 6408, entre 64 y 66
San José de las Lajas, Provincia Habana / CU
05 / PEREZ RODRIGUEZ, Rolando
Juan Delgado 567 e/. Acosta y O'farrill, 10 de Oc t.
Ciudad De La Habana / CU
Representative(s)Schüssler, Andrea
Kanzlei Huber & Schüssler
Truderinger Strasse 246
81825 München / DE
[2020/10]
Former [2009/47]Hatzmann, Martin, et al
Vereenigde Johan de Wittlaan 7
2517 JR Den Haag / NL
Application number, filing date07855983.824.12.2007
[2009/47]
WO2007CU00021
Priority number, dateCU2006000025026.12.2006         Original published format: CU 20060250
[2009/47]
Filing languageES
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008077355
Date:03.07.2008
Language:ES
[2008/27]
Type: A1 Application with search report 
No.:EP2119452
Date:18.11.2009
Language:EN
[2009/47]
Type: B1 Patent specification 
No.:EP2119452
Date:04.03.2020
Language:EN
[2020/10]
Search report(s)International search report - published on:ES03.07.2008
(Supplementary) European search report - dispatched on:EP09.05.2012
ClassificationIPC:A61K39/00, C07K16/28
[2014/25]
CPC:
C07K16/2896 (EP,US); A61K39/395 (KR); A61K39/3955 (US);
A61K45/06 (US); A61K9/0019 (US); A61P19/02 (EP);
A61P29/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61K2039/505 (EP,US); C07K2317/14 (US); C07K2317/24 (EP,US);
C07K2317/73 (EP,US) (-)
Former IPC [2009/47]A61K39/395, C07K16/28, A61P37/02
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2020/10]
Former [2009/47]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL21.07.2009
BA21.07.2009
HR21.07.2009
MK21.07.2009
RS21.07.2009
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT EINEM ANTI-CD6-MONOKLONALEN ANTIKÖRPER BEI DER DIAGNOSE UND BEHANDLUNG VON RHEUMATOIDER ARTHRITIS[2009/47]
English:PHARMACEUTICAL COMPOSITION, COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS[2009/47]
French:COMPOSITION PHARMACEUTIQUE CONTENANT UN ANTICORPS MONOCLONAL ANTI-CD6 UTILISE DANS LE DIAGNOSTIC ET LE TRAITEMENT DE L'ARTHRITE RHUMATOIDE[2009/47]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase21.07.2009Translation filed 
21.07.2009National basic fee paid 
21.07.2009Search fee paid 
21.07.2009Designation fee(s) paid 
21.07.2009Examination fee paid 
Examination procedure21.07.2009Examination requested  [2009/47]
27.11.2012Amendment by applicant (claims and/or description)
13.02.2013Despatch of a communication from the examining division (Time limit: M04)
10.06.2013Reply to a communication from the examining division
30.05.2014Despatch of a communication from the examining division (Time limit: M06)
07.11.2014Reply to a communication from the examining division
20.10.2015Date of oral proceedings
07.01.2016Despatch of communication that the application is refused, reason: substantive examination {1}
07.01.2016Minutes of oral proceedings despatched
30.10.2019Communication of intention to grant the patent
23.01.2020Fee for grant paid
23.01.2020Fee for publishing/printing paid
23.01.2020Receipt of the translation of the claim(s)
Appeal following examination04.03.2016Appeal received No.  T1481/16
17.05.2016Statement of grounds filed
16.04.2019Result of appeal procedure: remittal for grant
16.04.2019Date of oral proceedings
30.04.2019Minutes of oral proceedings despatched
Divisional application(s)EP19169359.7   Application deemed to be withdrawn  : 16.05.2019
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.02.2013
Opposition(s)07.12.2020No opposition filed within time limit [2021/06]
Fees paidRenewal fee
15.12.2009Renewal fee patent year 03
30.12.2010Renewal fee patent year 04
16.12.2011Renewal fee patent year 05
17.12.2012Renewal fee patent year 06
16.12.2013Renewal fee patent year 07
28.11.2014Renewal fee patent year 08
22.12.2015Renewal fee patent year 09
29.12.2016Renewal fee patent year 10
27.12.2017Renewal fee patent year 11
31.12.2018Renewal fee patent year 12
31.12.2019Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.12.2007
AT04.03.2020
CY04.03.2020
CZ04.03.2020
EE04.03.2020
FI04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
MT04.03.2020
RO04.03.2020
SI04.03.2020
SK04.03.2020
TR04.03.2020
BG04.06.2020
IS04.07.2020
[2022/27]
Former [2022/26]AT04.03.2020
CZ04.03.2020
EE04.03.2020
FI04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
RO04.03.2020
SI04.03.2020
SK04.03.2020
TR04.03.2020
BG04.06.2020
IS04.07.2020
Former [2021/40]AT04.03.2020
CZ04.03.2020
EE04.03.2020
FI04.03.2020
LT04.03.2020
LV04.03.2020
MC04.03.2020
RO04.03.2020
SI04.03.2020
SK04.03.2020
BG04.06.2020
IS04.07.2020
Former [2021/11]AT04.03.2020
CZ04.03.2020
EE04.03.2020
FI04.03.2020
LT04.03.2020
LV04.03.2020
RO04.03.2020
SI04.03.2020
SK04.03.2020
BG04.06.2020
IS04.07.2020
Former [2020/50]CZ04.03.2020
EE04.03.2020
FI04.03.2020
LT04.03.2020
LV04.03.2020
RO04.03.2020
SK04.03.2020
BG04.06.2020
IS04.07.2020
Former [2020/49]CZ04.03.2020
FI04.03.2020
LT04.03.2020
LV04.03.2020
RO04.03.2020
SK04.03.2020
BG04.06.2020
IS04.07.2020
Former [2020/47]FI04.03.2020
LT04.03.2020
LV04.03.2020
BG04.06.2020
IS04.07.2020
Former [2020/46]FI04.03.2020
LV04.03.2020
BG04.06.2020
IS04.07.2020
Former [2020/39]FI04.03.2020
LV04.03.2020
BG04.06.2020
Former [2020/38]FI04.03.2020
LV04.03.2020
Former [2020/35]FI04.03.2020
Documents cited:Search[Y] US6572857  (CASIMIRO JOSE ENRIQUE MONTERO et al.) [Y] 1-11 * example 2; claim 1 *
 [Y] WO0067796  (GENENTECH INC et al.) [Y] 3-6 * page 3, line 17 * * page 1, lines 3-4 * * page 8, line 22 - page 10, line 8 *
 [XY] US6372215  (STARLING GARY C et al.) [X] 1 * paragraphs [0076] , [0085] , [0092] *[Y] 2,8-11
 [Y]   JOO YEONG-SHIL ET AL: "Evidence for the expression of a second CD6 ligand by synovial fibroblasts", ARTHRITIS AND RHEUMATISM, vol. 43, no. 2, February 2000 (2000-02-01), pages 329 - 335, XP002669703, ISSN: 0004-3591 [Y] 1-11 * Abstract, Discussion (closing paragraph) *

DOI:   http://dx.doi.org/10.1002/1529-0131(200002)43:2<329::AID-ANR12>3.0.CO;2-Y
International search[X] WO9512614  (UNIV DUKE et al.)
 [Y] WO9719111  (INMUNOLOGIA MOLECULAR CIM CENT et al.)
 [A] WO9843089  (BRISTOL MYERS SQUIBB CO et al.)
 [A] ES2192128  (UNIV VIGO et al.)
 [A] ES2254174  (GENENTECH INC et al.)
ExaminationEP0807125
   E MONTERO ET AL, ARTHRITIS RESEARCH, vol. 4, no. Suppl 1, 1 January 2002 (2002-01-01), pages 114, XP055118708, ISSN: 1465-9905, DOI: 10.1186/ar450 [Y] 1-11 * Abstract, Discussion (closing paragraph) *

DOI:   http://dx.doi.org/10.1186/ar450
by applicantUS6372215
 US699755
 EP0807125
   SMOLEN, J.S. ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 2, 2003, pages 473
   FELDMANN, M. ET AL., NATURE, vol. 435, 2005, pages 612
   GARBER, K., NATURE BIOTECHNOLOGY, vol. 23, no. 11, 2005, pages 1323
   OLSEN, N.J. ET AL., N ENGL J MED, vol. 350, 2004, pages 2167
   PINCUS, T. ET AL., ANN INTERN MED, vol. 131, 1999, pages 768
   O'DELL, J.R., N ENGL J MED, vol. 350, 2004, pages 2591
   EDWARDS, J.C. ET AL., N ENGL J MED, vol. 350, 2004, pages 2572
   STOHL, W. ET AL., CLINICAL IMMUNOLOGY, vol. 121, 2006, pages 1
   BROWNING, J.L., NATURE REVIEWS DRUG DISCOVERY, vol. 5, 2006, pages 564
   KAHAN, B.D., NATURE REVIEWS IMMUNOLOGY, vol. 3, 2003, pages 831
   HALE, D.A., CURRENT OPINION IMMUNOLOGY, vol. 16, 2004, pages 565
   GOLDBLATT, F. ET AL., CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 140, 2005, pages 195
   TAYLOR, P.C. ET AL., CURRENT OPINION PHARMACOLOGY, vol. 4, 2004, pages 368
   ARUFFO, A. ET AL., IMMUNOL TODAY, vol. 18, no. 10, 1997, pages 498
   PATEL, D.D., J BIOL REGUL HOMEOST AGENTS, vol. 14, no. 3, 2000, pages 234
   SINGER, N.G. ET AL., INT IMMUNOL., vol. 14, no. 6, 2002, pages 585
   MONTERO, E. ET AL., AUTOIMMUNITY, vol. 29, no. 2, 1999, pages 155
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.